Department of Oncology, Zhengzhou University First Affiliated Hospital; Lymphoma Diagnosis and Treatment Center of Henan Province, Νo. 1 Jianshe East Road, Zhengzhou, Henan, China.
Department of Pathology, Zhengzhou University First Affiliated Hospital, Νo. 1 Jianshe East Road, Zhengzhou, Henan, China.
J Hematol Oncol. 2018 Jan 31;11(1):15. doi: 10.1186/s13045-018-0559-7.
Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet, and efforts to further improve treatment are urgently needed. Herein, seven patients with NKTCL who failed to respond to various types of chemotherapies were treated with the anti-programmed death 1 (anti-PD-1) antibody pembrolizumab at 100 mg every 3 weeks. After a median of four cycles of treatment (range 2-18), four out of seven patients responded (two complete response, two partial response, overall response rate 57%). Expression of PD1-ligand available was 50, 20, 30, 70, and 30% of five patients respectively. It is negative in one patient and not tested in one patient. Adverse events, which mostly ranged from grade I to grade III, were tolerable and could be safely handled, although immune-related pneumonitis was notable. Overall, PD-1 blockade with pembrolizumab represents a favorable strategy for the treatment of refractory/relapsed NKTCL.
自然杀伤细胞/T 细胞淋巴瘤（NKTCL）是一种罕见的非霍奇金淋巴瘤亚型，与预后不良相关。目前，NKTCL 的治疗需求尚未得到满足，迫切需要进一步改善治疗方法。在此，我们报告了 7 例对各种类型化疗反应不佳的 NKTCL 患者，采用每 3 周 100mg 的抗程序性死亡受体 1（anti-PD-1）抗体派姆单抗进行治疗。在中位 4 个周期的治疗（范围 2-18）后，7 例患者中有 4 例（2 例完全缓解，2 例部分缓解，总缓解率为 57%）有反应。5 例患者的 PD1 配体表达分别为 50%、20%、30%、70%和 30%。1 例患者为阴性，1 例患者未检测。大多数不良反应为 1-3 级，可耐受且可安全处理，尽管免疫相关性肺炎较为显著。总之，派姆单抗的 PD-1 阻断代表了治疗难治/复发 NKTCL 的一种有利策略。
Zotero 插件
